SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-035848
Filing Date
2024-08-08
Accepted
2024-08-08 06:40:06
Documents
15
Period of Report
2024-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20240808.htm   iXBRL 8-K 29847
2 EX-99.1 a991pressreleasedatedaugus.htm EX-99.1 111524
6 x4logoa.jpg GRAPHIC 4345
  Complete submission text file 0001628280-24-035848.txt   290990

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20240808.xsd EX-101.SCH 1904
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20240808_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20240808_pre.xml EX-101.PRE 13583
17 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20240808_htm.xml XML 2824
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 241185899
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)